In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of ...
The causative agent of the coronavirus disease 2019 (COVID-19) – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – was first detected in Wuhan, China, in December 2019. To date, the virus ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
Madhi et al. (May 20 issue) 1 report on the efficacy of vaccination with the recombinant adenoviral vector encoding the spike protein antigen of SARS-CoV-2 (ChAdOx1 nCoV-19) against the SARS-CoV-2 B.1 ...
The recombinant vector vaccines segment accounted for a market share of more than 11% in the global veterinary market in 2016. Recombinant vector vaccines mimic a natural process of infection, but ...
Please provide your email address to receive an email when new articles are posted on . According to the CDC, manufacturers expect to deliver 188 million to 200 million doses of influenza vaccine in ...
Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...
Since February 2021, very rare cases of thrombosis with thrombocytopenia syndrome, later named vaccine-induced immune thrombocytopenia and thrombosis (VITT) have been reported after receipt of the ...
The recombinant zoster vaccine (Shingrix) was associated with a 17% increase in time without a dementia diagnosis, compared with the live vaccine. This translated into 164 additional days without a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results